Basic information Safety Related Supplier

ChemicalBook Product Catalog A77 1726

1/2

A77 1726

$ 1.00 /1KG

Min. Order1G
Purity98%
Cas No163451-81-8
Supply Ability100KG
Update time2019-07-06

career henan chemical co

career henan chemical co

6YR

China

show more

Chemical Properties

Product Name	A77 1726
CAS No	163451-81-8
EC-No
Min. Order	1G
Purity	98%
Supply Ability	100KG
Release date	2019/07/06

AD68

A77 1726 Basic information

Product Name:	A77 1726
Synonyms:	A77 1726 (Teriflunomide);LeflunoMide EP IMpurity B;A 1726;Flucyamide;HMR 1726;(Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
CAS:	163451-81-8
MF:	C12H9F3N2O2
MW:	270.2072696
EINECS:	1308068-626-2
Product Categories:	Metabolites & Impurities;Tyrosine Kinase Inhibitors
Mol File:	163451-81-8.mol

A77 1726 Chemical Properties

Melting point	229-232°C
storage temp.	Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility	DMSO: soluble5mg/mL, clear (warmed)
color	white to beige
λmax	203nm(MeOH)(lit.)
Merck	14,9165
InChIKey	UTNUDOFZCWSZMS-YFHOEESVSA-N

Safety Information

Hazard Codes	Xn
Risk Statements	22

MSDS Information

A77 1726 Usage And Synthesis

Chemical Properties	White Solid
Uses	The active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function.
Definition	ChEBI: An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis.
Uses	A-771726 is the active metabolite of leflunomide, a prodrug approved by the FDA for treatment of rheumatoid arthritis. A-771726 reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines. It prevents activated lymphocytes from accumulating sufficient pyrimidines to support DNA synthesis (IC50s = 0.09, 3.5, and 12.5 μM for rat, mouse, and human, respectively). At higher doses, A-771726 inhibits tyrosine kinases responsible for early T cell and B cell signaling in the G0/G1 phase of the cell cycle. A-771726 has also been shown to inhibit the production of prostaglandin E2 in synoviocytes activated by TNF-α and IL-1α (IC50s = 7 and 3 μM, respectively) as well as inhibit MMP-1 and IL-6 production at concentrations >10 μM.[Cayman Chemical]

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book